Market Overview - The Shanghai Composite Index experienced a rare 13 consecutive days of gains, breaking the previous high from November 14, 2025, and reaching a new high since July 2015, closing up by 1.50% [1] - The market saw over 4,100 stocks in the green, with significant contributions from financial sectors such as brokerage, insurance, and internet finance [1] Seasonal Trends - According to Zheshang Securities, the first quarter typically sees a "spring rally," where small and mid-cap growth indices perform best, setting the stage for February's market performance [1] Key Sectors Financial Sector - Major financial stocks like Dazhihui and Hualin Securities hit the daily limit, while China Ping An reached a new five-year high [1] Brain-Computer Interface - The brain-computer interface sector saw a surge, with nearly 20 stocks hitting the daily limit, driven by breakthroughs in clinical trials for a new fully implanted device [3] - The industry is expected to enter a critical phase of large-scale application, supported by policy backing and ongoing technological advancements [3] Non-Ferrous Metals - The non-ferrous metals sector strengthened, with companies like Luoyang Molybdenum and Zijin Mining reaching historical highs, influenced by rising global metal prices [4] - The London Metal Exchange reported significant price increases for tin and copper, indicating strong demand and supply dynamics [4] Solid-State Batteries - The solid-state battery sector experienced a rally, with several stocks hitting the daily limit, following the announcement of a commercially viable solid-state battery by Donut Lab [5] - The sector is expected to progress towards industrialization, supported by policy focus and active participation from industry players [5] Semiconductor Sector - The semiconductor sector remained active, with storage chips and semiconductor equipment leading the gains, as companies like Beifang Huachuang reached historical highs [6] - Price increases for DRAM chips were reported, with significant hikes expected in Q1 2026 [7] Institutional Insights - Guotai Junan Securities highlighted the internal trend of a "transformation bull market" in China, driven by economic shifts and capital market reforms [8] - Debon Securities expressed optimism for a slow bull market following the New Year, with expectations for continued upward movement in the A-share market [8] - Dongfang Securities noted that the market's upward trend is supported by strong investor confidence and the commercialization of new industries like brain-computer interfaces and AI [9]

Group 1 - The core focus of the news is the explosive growth of the brain-computer interface (BCI) sector in the A-share market, with significant stock price increases observed on the first trading day of 2026, particularly for companies involved in BCI technology [1][5] - Notable stock performances include BeiYikang with a 30% increase, and other companies like Sanbo Brain Science, Xiangyu Medical, and Meihai Medical all achieving around 20% gains [1][5] - The surge in the BCI sector is attributed to three major developments: Neuralink's announcement of large-scale production of BCI devices, the implementation of new industry standards in China, and successful clinical trials demonstrating the technology's effectiveness [3][4][6] Group 2 - Neuralink, led by Elon Musk, announced that its BCI devices will enter mass production in 2026, along with a breakthrough in automated surgical technology for implanting devices [3] - A new industry standard for BCI medical devices in China, effective January 1, 2026, aims to provide regulatory clarity and facilitate clinical trials and product approvals [4] - A successful human trial in China demonstrated the ability to restore movement in paralyzed patients using implanted electrodes, showcasing rapid advancements in BCI technology [6] Group 3 - Investment interest in the BCI sector is heightened, with major international banks like Goldman Sachs, BNP Paribas, and Morgan Stanley focusing on companies like Innovation Medical, which has a strategic advantage due to its hospital resources [8] - The global BCI market is projected to reach $12.4 billion by 2034, with a compound annual growth rate of 17% from 2025 to 2034, indicating strong long-term growth potential [9] - The potential applications of BCI technology are expanding beyond medical uses, with possibilities in consumer electronics and smart home integration, suggesting a broader market impact [11] Group 4 - Despite the excitement, challenges remain in ensuring the long-term viability of implanted electrodes and improving the accuracy of non-invasive BCI systems [12] - Following the stock price surge, regulatory bodies have issued inquiries to several companies in the BCI sector to ensure transparency regarding their business operations and R&D progress [12] - Innovation Medical's stock has seen significant increases, but analysts caution that its current valuation is high, and investors should monitor the actual progress of its BCI projects and their impact on profitability [14]

创新医疗、倍益康、三博脑科、南京熊猫、美好医疗涨停，熵基科技涨超15%，麦澜德、爱朋医疗涨超 10%。 (本文来自第一财经) ...

另外，马斯克近日在社交媒体上表示，其脑机接口公司Neuralink将于2026年开始对脑机接口设备进 行"大规模生产"。 | 代码 | 名称 | | 涨幅% ↓ | 总市值 | 年初至今涨幅% | | --- | --- | --- | --- | --- | --- | | 688580 | 伟思医疗 | 1 | 20.01 | 66.75亿 | 44.01 | | 301293 | 三博脑科 | 1 | 20.01 | 175亿 | 44.01 | | 688626 | 翔宇医疗 | 1 | 20.00 | 139亿 | 44.00 | | 300753 | 爰朋医疗 | 1 | 20.00 | 50.37 乙 | 44.00 | | 301330 | 熵基科技 | 1 | 19.99 | 112亿 | 43.99 | | 301363 | 美好医疗 | 1 | 19.99 | 197亿 | 43.99 | | 688273 | 麦澜德 | 1 | 19.99 | 61.22 亿 | 43.98 | | 300430 | 诚益通 | 1 | 18.47 | 74.60亿 | 42.14 | | 30040 ...

非银金融板块盘中快速拉升，其中被视为"牛市旗手"或"市场风向标"的券商股强劲上行，华林证券（002945）冲上涨停，华安证券（600909）、东北证券 等多股大涨。 | < ロ | 券商指数(886054) 11968.03 392.47 +3.39% | | | O | | --- | --- | --- | --- | --- | | 资料 | 资讯 成分 | | 相关基金 | 月度收益 | | 华林证券 | | 17.84 | 9.99% | 0.00% | | 002945.SZ | | | | | | 华安证券 | | 7.58 | 9.70% | -0.26% | | 600909.SH | | | | | 1月6日，沪指高开高走，截至午盘收盘，沪指涨1.14%，创十年新高。深成指涨0.81%，创业板指跌0.04%。沪深两市半日成交额1.8万亿，较上个交易日放 量1455亿，全市场近3700只个股上涨。 | 上证指数 | 深证成指 | 科创综指 | | --- | --- | --- | | 4069.38 | 13940.24 | 1713.58 | | +45.96 +1.14% +111.6 ...

Core Insights - The competition for brain-computer interface (BCI) technology is intensifying, with significant implications for human interaction and technology, comparable to the advent of the internet [1] - China is making strategic investments in BCI technology, aiming to establish itself as a leader in this emerging field [5] Technology Overview - BCI technology establishes a direct connection between the brain and external devices, translating neural signals into commands for machines, enabling functionalities like mobility for paralyzed individuals and communication for those unable to speak [2] - There are three main types of BCI technologies: non-invasive, semi-invasive, and invasive, each with varying levels of risk and signal quality [3] Industry Development - By 2025, China aims to achieve significant breakthroughs in BCI technology, with plans to create several industrial clusters and nurture global leaders in the field by 2030 [5] - The inclusion of BCI in China's national economic planning marks a shift from research to a strategic focus on technological advancement [5] Clinical Advancements - Clinical trials for invasive BCI technologies are progressing, with companies like Neuralink and domestic firms achieving significant milestones in patient treatments [6][7] - Non-invasive BCI applications are also expanding in medical and consumer markets, with several companies preparing to launch products [7] Market Growth - The global BCI market is projected to grow from $1.2 billion in 2019 to nearly $2 billion in 2023, with a compound annual growth rate (CAGR) exceeding 13% [9] - China's BCI market is expected to reach approximately $3.2 billion in 2024, with further growth anticipated [10] Investment Landscape - Investment in the BCI sector has seen fluctuations, with a peak in 2021-2022, but is expected to rebound due to supportive policies and government initiatives [11] - Most funding is directed towards invasive BCI solutions, with a significant number of investments occurring in early-stage rounds [11] Key Players - Companies involved in BCI technology span various sectors, including those focused on core components like electrodes and chips, as well as those developing applications in healthcare and consumer products [13][14][15] - Notable companies include Sanbo Brain Science, which has participated in pioneering clinical trials, and Yingqu Technology, a leading player in BCI device sales [17][18]

Market Performance - The Shanghai Composite Index rose by 1.14% to 4069.38 points, reaching a new high in over 10 years [1] - The Shenzhen Component Index increased by 0.81% to 13940.24 points, while the ChiNext Index fell by 0.04% to 3293.18 points [1] - The total trading volume in the Shanghai and Shenzhen markets was 178.13 billion yuan, with over 3600 stocks rising [1] Sector Performance - The leading sectors included brain-computer interfaces, chemical engineering, non-ferrous metals, insurance, securities, semiconductors, and photovoltaic equipment [2][3] - The non-ferrous metals sector saw a significant increase of 4.05%, while non-bank financials and oil & petrochemicals rose by 3.27% and 2.95%, respectively [3] - The brain-computer interface sector experienced a surge, with multiple stocks hitting the daily limit [3] Institutional Insights - Huatai Securities anticipates a strengthening spring market, recommending investments in growth sectors such as electric equipment and renewable energy, as well as domestic demand improvement themes [4] - CITIC Securities suggests that the cross-year market will exhibit characteristics of "growth leading and liquor accumulating," with a focus on sectors like snacks and dairy [5] - Guoxin Securities predicts that 2026 will be a significant year for the market, supported by favorable macro policies and improving corporate earnings [6] Emerging Opportunities - Guoxin Securities highlights the potential for 2026 to be the year of reusable commercial rockets, driven by the need for cost-effective launch solutions [7] - Tianfeng Securities expresses optimism about the growth potential in high-end consumer sectors such as cosmetics, gold jewelry, and duty-free shopping [8]

本报记者 刘钊 1月6日开盘，A股脑机接口概念板块延续强势，多只个股快速封板。截至记者发稿，其中伟思医疗（688580.SH）、三 博脑科（301293）（301293.SZ)、翔宇医疗（688626.SH）、爱朋医疗（300753）（300753.SZ)、美好医疗（301363） （301363.SZ）等多只个股20cm涨停，麦澜德（688273.SH）、诚益通（300430）（300430.SZ）、熵基科技 （301330）（301330.SZ）、博拓生物（688767.SH）等多只个股涨幅居前。 | 물을 | 代码 | 名称 | | 最新 | 涨幅% ↓ | 涨跌 | 成交量 | | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 688580 | 伟思医疗 | 1 | 69.70 | 20.01 | 11.62 | 8.70万 | | 2 | 301293 | 三博脑科 | 1 | 84.94 | 20.01 | 14.16 | 2.63万 | | 3 | 688626 | 翔宇医疗 | 1 | 87.12 | 20.00 | 14.52 | ...

Core Viewpoint - The medical ETF (512170) has shown significant performance, with a daily increase of over 5% and reaching a 20-day high, indicating strong market interest and potential growth in the healthcare sector [1]. Group 1: ETF Performance - The medical ETF opened high on January 6 and saw a peak increase of over 1%, with a trading volume exceeding 350 million yuan [1]. - The ETF has recorded five consecutive days of gains, reflecting a robust upward trend in the healthcare sector [1]. Group 2: Component Stocks - Brain-computer interface stocks, specifically Sanbo Brain Science and Meihua Medical, both hit the daily limit up of 20%, marking two consecutive days of gains [1]. - Conversely, the CXO sector experienced a pullback, with Tigermed seeing a decline of over 1% [1]. Group 3: Market Insights - Tesla CEO Elon Musk announced that Neuralink plans to start large-scale production of brain-computer interface devices in 2026, which could accelerate the commercialization of this technology [2]. - The National Medical Products Administration of China held a meeting to expedite the review and approval of related medical devices, indicating regulatory support for the industry [2]. Group 4: Industry Outlook - CITIC Securities highlighted that China's brain-computer interface technology is relatively advanced globally, which may lead to the emergence of leading companies in this field and enhance valuations in the secondary market [3]. - Zhongtai Securities noted a potential rebound in the pharmaceutical sector after four years of decline, driven by the realization of innovative drug export logic and industry recovery due to policy reforms [3].

早盘，人脑工程板块表现活跃。板块内11只个股涨停。三博脑科、翔宇医疗、爱朋医疗、美好医疗 20CM涨停，伟思医疗涨超19%，麦澜德、诚益通涨超14%，熵基科技涨超12%，道氏技术、博拓生物 涨超10%，创新医疗、普利特、岩山科技、塞力医疗、盈趣科技、南京熊猫、国际医学涨停。 消息面上，马斯克旗下Neuralink宣布将在2026年启动脑机接口设备大规模生产，同步推进流程高度精 简、几乎完全自动化的手术方案，电极丝可直接穿过硬脑膜无需切除，有效规避传统侵入式设备的创伤 性瓶颈，实现效率与成本的双向优化。 同时，OpenAI首席执行官Sam Altman参与创立的脑机接口初创公司MergeLabs完成分拆独立，将专注于 超声波读取脑部活动技术研发，无需植入电极即可大范围解读大脑信号，为脑机接口应用提供全新技术 路径。 脑机接口核心技术研发：作为人脑工程的核心赛道，掌握信号采集、算法处理等核心技术的企业将率先 受益于行业技术迭代与商业化落地。随着侵入式与非侵入式技术同步推进，具备自主研发能力、拥有技 术壁垒的企业将抢占市场先机，分享行业高速增长红利。 医疗设备制造：脑机接口的商业化应用需要大量定制化医疗设备支持，包 ...